Advancing your drug or vaccine candidate from late-stage discovery into the clinic is one of the most critical steps in development. This is the phase when you make key decisions that will have long-term scientific and business impact, frequently under extreme time and cost pressure.
Our protein design and optimization services help identify and mitigate manufacturing and development risks, reduce attrition and improve the quality and safety of therapeutic proteins.
In this early phase it is critical to have access to experts that understand your development journey. Your tailored conversation topics can include:
De-risking your lead
Assessment and manufacturability screening
Protein engineering
Humanisation
Preventing an unwanted immune response
• De-immunization
• Immunogenicity
Generating materials for your in vitro and preclinical studies
• Non-GMP protein expression and supply
• Guaranteed antibody supply up to 2 g within 6 weeks
Compliance with regulatory guidance for IND
• In-silico and in-vitro immunogenicity/immunotoxicity assessment
Learn more here.
To schedule a meeting, send an E-mail to Mattias Nystrom
Senior Business Development Manager, Nordic countries
